FI923446A0 - FOERFARANDE OCH KOMPOSITIONER FOER SYNTES AV BCH-189 OCH LIKNANDE FOERENINGAR. - Google Patents

FOERFARANDE OCH KOMPOSITIONER FOER SYNTES AV BCH-189 OCH LIKNANDE FOERENINGAR.

Info

Publication number
FI923446A0
FI923446A0 FI923446A FI923446A FI923446A0 FI 923446 A0 FI923446 A0 FI 923446A0 FI 923446 A FI923446 A FI 923446A FI 923446 A FI923446 A FI 923446A FI 923446 A0 FI923446 A0 FI 923446A0
Authority
FI
Finland
Prior art keywords
bch
och
syntes
foereningar
foer
Prior art date
Application number
FI923446A
Other languages
Finnish (fi)
Other versions
FI923446A (en
FI114471B (en
Inventor
Dennis C Liotta
Woo-Baeg Choi
Original Assignee
Univ Emory
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23879071&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FI923446(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ Emory filed Critical Univ Emory
Publication of FI923446A publication Critical patent/FI923446A/en
Publication of FI923446A0 publication Critical patent/FI923446A0/en
Application granted granted Critical
Publication of FI114471B publication Critical patent/FI114471B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D327/00—Heterocyclic compounds containing rings having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D327/02—Heterocyclic compounds containing rings having oxygen and sulfur atoms as the only ring hetero atoms one oxygen atom and one sulfur atom
    • C07D327/04—Five-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D411/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D411/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D411/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids

Abstract

The present invention relates to a method of preparing BCH-189 and various analogues of BCH-189 from inexpensive precursors with the option of introducing functionality as needed. This synthetic route allows the stereoselective preparation of the biologically active isomer of these compounds, ²-BCH-189 and related compounds. Furthermore, the stereochemistry at the nucleoside 4'-position can be controlled to produce enantiomerically-enriched ²-BCH-189 and its analogues.
FI923446A 1990-02-01 1992-07-30 Process for Preparation of the Beta Isomer of the Nucleoside 2 ', 3' -Dideoxy-3 '-tiapyrimidine FI114471B (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US47331890 1990-02-01
US07/473,318 US5204466A (en) 1990-02-01 1990-02-01 Method and compositions for the synthesis of bch-189 and related compounds
PCT/US1991/000685 WO1991011186A1 (en) 1990-02-01 1991-01-31 Method and compositions for the synthesis of bch-189 and related compounds
US9100685 1991-01-31

Publications (3)

Publication Number Publication Date
FI923446A FI923446A (en) 1992-07-30
FI923446A0 true FI923446A0 (en) 1992-07-30
FI114471B FI114471B (en) 2004-10-29

Family

ID=23879071

Family Applications (4)

Application Number Title Priority Date Filing Date
FI923446A FI114471B (en) 1990-02-01 1992-07-30 Process for Preparation of the Beta Isomer of the Nucleoside 2 ', 3' -Dideoxy-3 '-tiapyrimidine
FI20030933A FI116222B (en) 1990-02-01 2003-06-24 1,3-oxathiolane
FI20050672A FI121069B (en) 1990-02-01 2005-06-22 Process for the preparation of a mixture of isomers comprising 2′, 3′-dideoxy-3′-thia-pyrimidine nucleoside
FI20060622A FI20060622A (en) 1990-02-01 2006-06-27 A process for the preparation of a therapeutically useful beta-2-hydroxymethyl-5- (5-fluoro-cytosin-1-yl) -1,3-oxathiolane

Family Applications After (3)

Application Number Title Priority Date Filing Date
FI20030933A FI116222B (en) 1990-02-01 2003-06-24 1,3-oxathiolane
FI20050672A FI121069B (en) 1990-02-01 2005-06-22 Process for the preparation of a mixture of isomers comprising 2′, 3′-dideoxy-3′-thia-pyrimidine nucleoside
FI20060622A FI20060622A (en) 1990-02-01 2006-06-27 A process for the preparation of a therapeutically useful beta-2-hydroxymethyl-5- (5-fluoro-cytosin-1-yl) -1,3-oxathiolane

Country Status (22)

Country Link
US (8) US5204466A (en)
EP (3) EP0872237B1 (en)
JP (6) JPH07618B2 (en)
KR (2) KR100381705B1 (en)
AT (1) ATE170750T1 (en)
AU (6) AU658136C (en)
BG (1) BG62236B1 (en)
CA (3) CA2481078C (en)
DE (4) DE513200T1 (en)
DK (2) DK0872237T3 (en)
ES (2) ES2279559T3 (en)
FI (4) FI114471B (en)
GR (1) GR950300024T1 (en)
HK (1) HK1014664A1 (en)
HU (4) HUT62566A (en)
LU (1) LU91073I2 (en)
MC (1) MC2233A1 (en)
NL (1) NL300148I2 (en)
NO (6) NO923014D0 (en)
RO (1) RO108564B1 (en)
RU (1) RU2125558C1 (en)
WO (1) WO1991011186A1 (en)

Families Citing this family (149)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6350753B1 (en) 1988-04-11 2002-02-26 Biochem Pharma Inc. 2-Substituted-4-substituted-1,3-dioxolanes and use thereof
US5047407A (en) * 1989-02-08 1991-09-10 Iaf Biochem International, Inc. 2-substituted-5-substituted-1,3-oxathiolanes with antiviral properties
US6175008B1 (en) * 1988-04-11 2001-01-16 Biochem Pharma Inc. Processes for preparing substituted 1,3-oxathiolanes with antiviral properties
US7119202B1 (en) 1989-02-08 2006-10-10 Glaxo Wellcome Inc. Substituted-1,3-oxathiolanes and substituted-1,3-dioxolanes with antiviral properties
US6903224B2 (en) 1988-04-11 2005-06-07 Biochem Pharma Inc. Substituted 1,3-oxathiolanes
US5466806A (en) * 1989-02-08 1995-11-14 Biochem Pharma Inc. Processes for preparing substituted 1,3-oxathiolanes with antiviral properties
ES2196004T3 (en) * 1989-02-08 2003-12-16 Iaf Biochem Int PROCEDURE TO PREPARE 1,3-OXATIOLANS SUBSTITUTED WITH ANTIVIRAL PROPERTIES.
US20090239887A1 (en) * 1990-02-01 2009-09-24 Emory University Method of resolution and antiviral activity of 1,3-oxathiolane nucleoside enantiomers
US5914331A (en) * 1990-02-01 1999-06-22 Emory University Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane
US6069252A (en) * 1990-02-01 2000-05-30 Emory University Method of resolution and antiviral activity of 1,3-oxathiolane nucleoside enantiomers
US6703396B1 (en) * 1990-02-01 2004-03-09 Emory University Method of resolution and antiviral activity of 1,3-oxathiolane nuclesoside enantiomers
US5204466A (en) * 1990-02-01 1993-04-20 Emory University Method and compositions for the synthesis of bch-189 and related compounds
US5276151A (en) * 1990-02-01 1994-01-04 Emory University Method of synthesis of 1,3-dioxolane nucleosides
GB9009861D0 (en) * 1990-05-02 1990-06-27 Glaxo Group Ltd Chemical compounds
US5444063A (en) * 1990-12-05 1995-08-22 Emory University Enantiomerically pure β-D-dioxolane nucleosides with selective anti-Hepatitis B virus activity
US5925643A (en) * 1990-12-05 1999-07-20 Emory University Enantiomerically pure β-D-dioxolane-nucleosides
IL100502A (en) * 1991-01-03 1995-12-08 Iaf Biochem Int Pharmaceutical compositions containing cis-4-amino-1(hydroxymethyl-1,3-oxathiolan-5-yl)-1H-pyrimid-2-one nucleoside or its derivatives
IL100965A (en) * 1991-02-22 1999-12-31 Univ Emory 2-Hydroxymethyl-5-(5-fluorocytosin-l-yl)-1,3-oxathiolane its resolution and pharmaceutical compositions containing it
US6812233B1 (en) 1991-03-06 2004-11-02 Emory University Therapeutic nucleosides
CA2105486C (en) * 1991-03-06 2003-10-28 George Robert Painter Iii Therapeutic nucleosides
GB9104740D0 (en) * 1991-03-06 1991-04-17 Wellcome Found Antiviral nucleoside combination
US5817667A (en) * 1991-04-17 1998-10-06 University Of Georgia Research Foudation Compounds and methods for the treatment of cancer
GB9109506D0 (en) * 1991-05-02 1991-06-26 Wellcome Found Therapeutic nucleosides
GB9110874D0 (en) * 1991-05-20 1991-07-10 Iaf Biochem Int Medicaments
ZA923640B (en) * 1991-05-21 1993-02-24 Iaf Biochem Int Processes for the diastereoselective synthesis of nucleosides
GB9111902D0 (en) * 1991-06-03 1991-07-24 Glaxo Group Ltd Chemical compounds
GB9116601D0 (en) * 1991-08-01 1991-09-18 Iaf Biochem Int 1,3-oxathiolane nucleoside analogues
US20050192299A1 (en) * 1992-04-16 2005-09-01 Yung-Chi Cheng Method of treating or preventing hepatitis B virus
GB9311709D0 (en) * 1993-06-07 1993-07-21 Iaf Biochem Int Stereoselective synthesis of nucleoside analogues using bicycle intermediate
US20020120130A1 (en) * 1993-09-10 2002-08-29 Gilles Gosselin 2' or 3' -deoxy and 2', 3' -dideoxy-beta-L-pentofuranonucleo-side compounds, method of preparation and application in therapy, especially as anti- viral agents
JPH09504785A (en) * 1993-09-10 1997-05-13 エモリー、ユニバーシティー Nucleosides with anti-hepatitis B virus activity
US5587362A (en) * 1994-01-28 1996-12-24 Univ. Of Ga Research Foundation L-nucleosides
IL113432A (en) 1994-04-23 2000-11-21 Glaxo Group Ltd Process for the diastereoselective synthesis of nucleoside analogues
IL115156A (en) * 1994-09-06 2000-07-16 Univ Georgia Pharmaceutical compositions for the treatment of cancer comprising 1-(2-hydroxymethyl-1,3-dioxolan-4-yl) cytosines
US5703058A (en) * 1995-01-27 1997-12-30 Emory University Compositions containing 5-fluoro-2',3'-didehydro-2',3'-dideoxycytidine or a mono-, di-, or triphosphate thereof and a second antiviral agent
US6391859B1 (en) 1995-01-27 2002-05-21 Emory University [5-Carboxamido or 5-fluoro]-[2′,3′-unsaturated or 3′-modified]-pyrimidine nucleosides
US5808040A (en) * 1995-01-30 1998-09-15 Yale University L-nucleosides incorporated into polymeric structure for stabilization of oligonucleotides
US6689761B1 (en) 1995-02-01 2004-02-10 Merck & Co., Inc. Combination therapy for HIV infection
MY115461A (en) 1995-03-30 2003-06-30 Wellcome Found Synergistic combinations of zidovudine, 1592u89 and 3tc
GB9506644D0 (en) * 1995-03-31 1995-05-24 Wellcome Found Preparation of nucleoside analogues
DE19514523A1 (en) * 1995-04-12 1996-10-17 Schering Ag New cytosine and cytidine derivatives
ES2276404T3 (en) 1995-06-07 2007-06-16 Emory University NUCLEOSIDS WITH ANTIVIRUS ACTIVITY OF HEPATITIS-B.
AP9801419A0 (en) 1996-06-25 1998-12-31 Glaxo Group Ltd Combination comprising VX478, zidovudine, FTC and or 3
US5753789A (en) * 1996-07-26 1998-05-19 Yale University Oligonucleotides containing L-nucleosides
US6113920A (en) * 1996-10-31 2000-09-05 Glaxo Wellcome Inc. Pharmaceutical compositions
US5792773A (en) * 1996-11-15 1998-08-11 Yale University L-β-dioxolane uridine analog administration for treating Epstein-Barr virus infection
US6022876A (en) * 1996-11-15 2000-02-08 Yale University L-β-dioxolane uridine analogs and methods for treating and preventing Epstein-Barr virus infections
WO1998041522A1 (en) * 1997-03-19 1998-09-24 Emory University Synthesis, anti-human immunodeficiency virus and anti-hepatitis b virus activities of 1,3-oxaselenolane nucleosides
EP0986375A2 (en) 1997-04-07 2000-03-22 Triangle Pharmaceuticals Inc. Use of mkc-442 in combination with other antiviral agents
EP1754710A3 (en) 1998-02-25 2007-12-19 Emory University 2'-Fluoroncucleosides
IL138037A0 (en) 1998-02-25 2001-10-31 Univ Emory 2'-fluoronucleosides
AU5475799A (en) * 1998-08-10 2000-03-06 Centre National De La Recherche Scientifique Beta-l-2'-deoxy-nucleosides for the treatment of hepatitis
US6444652B1 (en) * 1998-08-10 2002-09-03 Novirio Pharmaceuticals Limited β-L-2'-deoxy-nucleosides for the treatment of hepatitis B
CN1141305C (en) 1998-08-12 2004-03-10 三角药物公司 Manufacture of 1,3-oxathiolane nucleosides
US6979561B1 (en) * 1998-10-09 2005-12-27 Gilead Sciences, Inc. Non-homogeneous systems for the resolution of enantiomeric mixtures
EP1380303B1 (en) 1998-11-02 2008-09-17 Gilead Sciences, Inc. Combination therapy to treat hepatitis B virus
US6407077B1 (en) 1998-11-05 2002-06-18 Emory University β-L nucleosides for the treatment of HIV infection
CA2348470C (en) 1998-11-05 2007-06-05 Centre National De La Recherche Scientifique Nucleosides with anti-hepatitis b virus activity
BR9916849A (en) 1998-12-23 2001-10-30 Shire Biochem Inc Analogs of antiviral nucleosides
US7205404B1 (en) 1999-03-05 2007-04-17 Metabasis Therapeutics, Inc. Phosphorus-containing prodrugs
US6653318B1 (en) * 1999-07-21 2003-11-25 Yale University 5-(E)-Bromovinyl uracil analogues and related pyrimidine nucleosides as anti-viral agents and methods of use
EP1634888A3 (en) 1999-11-12 2007-11-21 Pharmasset, Inc. Synthesis of 2'-deoxy-L-nucleosides
CN1919860A (en) * 1999-11-12 2007-02-28 法玛赛特有限公司 Synthesis of 2'-deoxy-l-nucleosides
US6436948B1 (en) 2000-03-03 2002-08-20 University Of Georgia Research Foundation Inc. Method for the treatment of psoriasis and genital warts
CA2308559C (en) 2000-05-16 2005-07-26 Brantford Chemicals Inc. 1,3-oxathiolan-5-ones useful in the production of antiviral nucleoside analogues
MY164523A (en) * 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
CN1315862C (en) 2000-05-26 2007-05-16 艾登尼科斯（开曼）有限公司 Methods and compositions for treating flaviviruses and pestiviruses
US6787526B1 (en) 2000-05-26 2004-09-07 Idenix Pharmaceuticals, Inc. Methods of treating hepatitis delta virus infection with β-L-2′-deoxy-nucleosides
US6875751B2 (en) * 2000-06-15 2005-04-05 Idenix Pharmaceuticals, Inc. 3′-prodrugs of 2′-deoxy-β-L-nucleosides
AU2001278804A1 (en) * 2000-08-09 2002-02-18 Kolon Industries, Inc. 5'-deoxy-n-(substituted oxycarbonyl)-5-fluorocytosine and derivatives thereof, method of preparing same, and anticancer composition comprising same as active ingredients
US20030166606A1 (en) * 2000-08-09 2003-09-04 Kwan-Hee Kim 5'-deoxy-n-(substituted oxycarbonyl)-5-fluorocytosine and derivatives thereof, method of preparing same, and anticancer composition comprising same as active ingredients
US20030228320A1 (en) * 2000-08-18 2003-12-11 Ashdown Martin Leonard Retroviral immunotherapy
CN1646141B (en) 2000-10-18 2014-06-25 吉利德制药有限责任公司 Modified nucleosides for treatment of viral infections and abnormal cellular proliferation
DE10104231A1 (en) 2001-01-31 2002-08-08 Consortium Elektrochem Ind Process for the enzymatic production of enantiomerically pure 1,3-dioxolan-4-one derivatives
DK1574512T3 (en) * 2001-03-01 2008-03-03 Abbott Lab Polymorphic and other crystalline forms of cis-FTC
CA2380804A1 (en) * 2001-05-01 2002-11-01 Mitsui Chemicals, Inc. Method for producing cytosine nucleosides compounds
US6600044B2 (en) 2001-06-18 2003-07-29 Brantford Chemicals Inc. Process for recovery of the desired cis-1,3-oxathiolane nucleosides from their undesired trans-isomers
ITMI20012317A1 (en) * 2001-11-06 2003-05-06 Recordati Ind Chimica E Farma DIASTEREOSELECTIVE PROCESS FOR THE PREPARATION OF THE ANTIVIRAL AGENT4-AMINO-1- (2R-IDROSSIMETIL- / 1,3 / OSSATIOLAN-5S-I1) -1H-PIRIMIDIN-2-ONE
EP1461041A4 (en) * 2001-12-14 2006-03-29 Pharmasset Ltd Preparation of intermediates useful in the synthesis of antiviral nucleosides
AUPS054702A0 (en) * 2002-02-14 2002-03-07 Immunaid Pty Ltd Cancer therapy
CN1329407C (en) * 2002-04-12 2007-08-01 阿奇林医药品公司 Method for synthesizing beta-L-fluoro-2',3'-dideoxy-didehydrocytidine (beta-L-FD4C)
US7608600B2 (en) * 2002-06-28 2009-10-27 Idenix Pharmaceuticals, Inc. Modified 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections
NZ537662A (en) * 2002-06-28 2007-10-26 Idenix Cayman Ltd 2'-C-methyl-3'-O-L-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections
US7456155B2 (en) * 2002-06-28 2008-11-25 Idenix Pharmaceuticals, Inc. 2′-C-methyl-3′-O-L-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections
CA2494183C (en) 2002-08-06 2012-01-03 Kyoichi A. Watanabe Processes for preparing 1,3-dioxolane nucleosides
TWI244393B (en) 2002-08-06 2005-12-01 Idenix Pharmaceuticals Inc Crystalline and amorphous forms of beta-L-2'-deoxythymidine
PT1572095E (en) * 2002-09-13 2015-10-13 Novartis Ag Beta-l-2'-deoxynucleosides for use in the treatment of resistant hbv strains
EP1576138B1 (en) * 2002-11-15 2017-02-01 Idenix Pharmaceuticals LLC. 2'-methyl nucleosides in combination with interferon and flaviviridae mutation
BR0317113A (en) * 2002-12-09 2005-10-25 Univ Georgia Res Found Thymine dioxolane and combinations for use against hiv 3tc / azt resistant strains
KR20050109918A (en) * 2002-12-12 2005-11-22 이데닉스 (케이만) 리미티드 Process for the production of 2'-branched nucleosides
NZ540728A (en) 2003-01-14 2008-08-29 Gilead Sciences Inc Compositions and methods for combination antiviral therapy
ITMI20030578A1 (en) * 2003-03-24 2004-09-25 Clariant Lsm Italia Spa PROCESS AND INTERMEDIATES FOR THE PREPARATION OF EMTRICITABINE
EP1608629A1 (en) 2003-03-24 2005-12-28 F. Hoffmann-La Roche Ag Benzyl-pyridazinons as reverse transcriptase inhibitors
NZ544634A (en) * 2003-06-30 2009-10-30 Idenix Cayman Ltd Synthesis of beta-l-2-deoxy nucleosides
GB0317009D0 (en) 2003-07-21 2003-08-27 Univ Cardiff Chemical compounds
JP4931593B2 (en) * 2003-10-24 2012-05-16 イミュネイド ピーティーワイ リミテッド Method of treatment
CA2554782C (en) * 2004-02-03 2013-08-13 Emory University Methods to manufacture 1,3-dioxolane nucleosides
DK2258376T3 (en) 2004-07-27 2019-04-15 Gilead Sciences Inc Phosphonate analogues of HIV inhibitor compounds
JP4058057B2 (en) * 2005-04-26 2008-03-05 株式会社東芝 Sino-Japanese machine translation device, Sino-Japanese machine translation method and Sino-Japanese machine translation program
TWI375560B (en) * 2005-06-13 2012-11-01 Gilead Sciences Inc Composition comprising dry granulated emtricitabine and tenofovir df and method for making the same
TWI471145B (en) * 2005-06-13 2015-02-01 Bristol Myers Squibb & Gilead Sciences Llc Unitary pharmaceutical dosage form
JP2009515826A (en) 2005-10-19 2009-04-16 エフ．ホフマン−ラ ロシュ アーゲー Phenyl-acetamide NNRT inhibitor
US8076303B2 (en) 2005-12-13 2011-12-13 Spring Bank Pharmaceuticals, Inc. Nucleotide and oligonucleotide prodrugs
EP1976382B1 (en) * 2005-12-23 2013-04-24 IDENIX Pharmaceuticals, Inc. Process for preparing a synthetic intermediate for preparation of branched nucleosides
US20090093016A1 (en) * 2006-01-17 2009-04-09 N.V. Organon Selective Enzymatic Hydrolysis of C-Terminal Tert-Butyl Esters of Peptides
US9044509B2 (en) 2006-02-03 2015-06-02 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Inhibition of HIV infection through chemoprophylaxis
US8895531B2 (en) * 2006-03-23 2014-11-25 Rfs Pharma Llc 2′-fluoronucleoside phosphonates as antiviral agents
ATE485292T1 (en) * 2006-04-18 2010-11-15 Lupin Ltd NEW CRYSTALLINE FORM OF LAMIVUDINE
AU2007275860C1 (en) 2006-07-07 2014-06-12 Gilead Sciences, Inc. Modulators of pharmacokinetic properties of therapeutics
BRPI0720436A2 (en) 2006-12-13 2014-01-07 Hoffmann La Roche NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS
LT3150586T (en) 2007-02-23 2020-03-10 Gilead Sciences, Inc. Modulators of pharmacokinetic properties of therapeutics
CN101307048B (en) * 2007-05-18 2011-03-23 上海迪赛诺医药发展有限公司 Method for preparing lamivadin by stereoselectivity
PL2159224T3 (en) 2007-06-18 2012-12-31 Ruyuan Wei Xiang Tech Co Ltd Bromo-phenyl substituted thiazolyl dihydropyrimidines
MX2010000424A (en) 2007-07-09 2010-08-10 Easter Virginia Medical School Substituted nucleoside derivatives with antiviral and antimicrobial properties.
WO2009052050A1 (en) * 2007-10-15 2009-04-23 Pharmasset, Inc. Dioxolane thymine phosphoramidates as anti-hiv agents
BRPI0820226A2 (en) * 2007-11-29 2015-06-16 Ranbaxy Lab Ltd Process for the preparation of a 1,3-oxathiolane, for the preparation of lamivudine and for the isolation of lamivudine, lamivudine and pharmaceutical composition
US20100311961A1 (en) * 2007-11-29 2010-12-09 Ranbaxy Laboratories Limited Process and intermediates for the preparation of substituted 1,3-oxathiolanes, especially lamivudine
WO2009107692A1 (en) 2008-02-29 2009-09-03 株式会社カネカ 2'-hydroxyl-protected ribonucleoside derivative and manufacturing method of same
US20110288298A1 (en) * 2008-11-12 2011-11-24 Lupin Limited novel polymorph of emtricitabine and a process for preparing of the same
NZ612380A (en) 2008-12-09 2015-01-30 Gilead Sciences Inc Modulators of toll-like receptors
US20110282046A1 (en) 2009-01-19 2011-11-17 Rama Shankar Process for preparation of cis-nucleoside derivative
KR101474570B1 (en) 2009-04-13 2014-12-19 주식회사 대희화학 New intermediate of Lamivudine and the preparation thereof
EP2435825B8 (en) 2009-05-27 2015-09-02 Biotempus Limited Methods of treating diseases
WO2011007367A1 (en) 2009-07-15 2011-01-20 Lupin Limited An improved process for preparation of efavirenz
WO2011095987A1 (en) 2010-02-03 2011-08-11 Matrix Laboratories Ltd. Novel process for the preparation of cis-nucleoside derivative
US20110223131A1 (en) 2010-02-24 2011-09-15 Gilead Sciences, Inc. Antiviral compounds
WO2011141805A2 (en) 2010-05-14 2011-11-17 Lupin Limited An improved process for the manufacture of lamivudine
EP2739620A1 (en) 2011-08-05 2014-06-11 Lupin Limited A stereoselective process for preparation of 1,3-oxathiolane nucleosides
CN102584800A (en) * 2011-12-16 2012-07-18 四川大学 Compound containing framework of chiral indolone and angelica lactone and asymmetric synthesis method
JP2015520144A (en) 2012-05-11 2015-07-16 アクロン・モレキュールズ・アクチェンゲゼルシャフトＡｋｒｏｎ Ｍｏｌｅｃｕｌｅｓ Ａｇ Use of compounds for the treatment of pain
HUE044605T2 (en) * 2012-11-16 2019-11-28 Univ College Cardiff Consultants Ltd Mixture of rp/sp gemcitabine-[phenyl-(benzyloxy-l-alaninyl)]-phosphate
SI2822954T1 (en) 2012-12-21 2016-07-29 Gilead Sciences, Inc. Polycyclic-carbamoylpyridone compounds and their pharmaceutical use
NO2865735T3 (en) 2013-07-12 2018-07-21
EP3252058B1 (en) 2013-07-12 2021-01-20 Gilead Sciences, Inc. Polycyclic-carbamoylpyridone compounds and their use for the treatment of hiv infections
CA2918707A1 (en) 2013-08-29 2015-03-05 Teva Pharmaceuticals Industries Ltd. Unit dosage form comprising emtricitabine, tenofovir, darunavir and ritonavir and a monolithic tablet comprising darunavir and ritonavir
CN106061984A (en) 2014-02-13 2016-10-26 配体药物公司 Prodrug compounds and their uses
CA2942877A1 (en) 2014-04-08 2015-10-15 Nitzan SHAHAR Unit dosage form comprising emtricitabine, tenofovir, darunavir and ritonavir
TWI744723B (en) 2014-06-20 2021-11-01 美商基利科學股份有限公司 Synthesis of polycyclic-carbamoylpyridone compounds
NO2717902T3 (en) 2014-06-20 2018-06-23
TW201613936A (en) 2014-06-20 2016-04-16 Gilead Sciences Inc Crystalline forms of(2R,5S,13aR)-8-hydroxy-7,9-dioxo-n-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazepine-10-carboxamide
WO2016001907A1 (en) 2014-07-02 2016-01-07 Prendergast Patrick T Mogroside iv and mogroside v as agonist/stimulator/un-blocking agent for toll-like receptor 4 and adjuvant for use in human/animal vaccine and to stimulate immunity against disease agents.
EP3164136A4 (en) 2014-07-02 2018-04-04 Ligand Pharmaceuticals, Inc. Prodrug compounds and uses therof
KR102019572B1 (en) 2014-07-11 2019-09-06 길리애드 사이언시즈, 인코포레이티드 Modulators of toll-like receptors for the treatment of hiv
WO2016033164A1 (en) 2014-08-26 2016-03-03 Enanta Pharmaceuticals, Inc. Nucleoside and nucleotide derivatives
TWI738321B (en) 2014-12-23 2021-09-01 美商基利科學股份有限公司 Polycyclic-carbamoylpyridone compounds and their pharmaceutical use
CA2980362C (en) 2015-04-02 2020-02-25 Gilead Sciences, Inc. Polycyclic-carbamoylpyridone compounds and their pharmaceutical use
US20170071944A1 (en) 2015-09-15 2017-03-16 Gilead Sciences, Inc. Modulators of toll-like receptors for the treatment of hiv
GB201610327D0 (en) * 2016-06-14 2016-07-27 Univ Nelson Mandela Metropolitan Process for producing Lamivudine and Entricitabine
JP2020515607A (en) 2017-03-31 2020-05-28 ザ ユニバーシティー オブ リヴァプール Prodrug composition

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4000137A (en) * 1975-06-10 1976-12-28 American Home Products Corporation Antitumor derivatives of periodate-oxidized nucleosides
JPS5259171A (en) * 1975-11-10 1977-05-16 Asahi Chem Ind Co Ltd Preparation of uracil derivatives
JPS6045196B2 (en) * 1976-08-09 1985-10-08 株式会社興人 Method for producing 1-(2-tetrahydrofuryl)uracils
JPS5668674A (en) * 1979-11-08 1981-06-09 Shionogi & Co Ltd 5-fluorouracil derivative
JPS5738774A (en) * 1980-08-19 1982-03-03 Chugai Pharmaceut Co Ltd Uracil derivative and its preparation
JPS5839672A (en) * 1981-09-03 1983-03-08 Chugai Pharmaceut Co Ltd Uracil derivative
DE3481191D1 (en) * 1983-07-20 1990-03-08 Teijin Ltd ANTINEOPLASTIC AGENT.
DE3534979A1 (en) * 1985-07-25 1987-01-29 Licentia Gmbh POWER SUPPLY
AU570853B2 (en) * 1985-08-26 1988-03-24 United States of America, as represented by the Secretary, U.S. Department of Commerce, The Inhibition of infectivity and cytopathic effect of htlv-111/ lav by purine bases
US4879277A (en) * 1985-08-26 1989-11-07 The United States Of America As Represented By The Department Of Health And Human Services Antiviral compositions and methods
GB2181128A (en) * 1985-09-17 1987-04-15 Wellcome Found 3'-azidonucleosides
US4916122A (en) * 1987-01-28 1990-04-10 University Of Georgia Research Foundation, Inc. 3'-Azido-2',3'-dideoxyuridine anti-retroviral composition
US4963533A (en) * 1986-10-24 1990-10-16 Stichting Rega Vzw (Rega) Therapeutic application of dideoxycytidinene
AU613026B2 (en) * 1987-03-24 1991-07-25 Nycomed As 2',3' dideoxyribofuranoxide derivatives
US5185437A (en) * 1987-04-09 1993-02-09 Burroughs Wellcome Co. Therapeutic nucleosides
US5011774A (en) * 1987-07-17 1991-04-30 Bristol-Myers Squibb Co. Dideoxyinosine by enzymatic deamination of dideoxyadenosine
US5047407A (en) * 1989-02-08 1991-09-10 Iaf Biochem International, Inc. 2-substituted-5-substituted-1,3-oxathiolanes with antiviral properties
NZ228645A (en) * 1988-04-11 1991-09-25 Iaf Biochem Int 1,3-dioxolane derivatives substituted in the 5th position by a purine or pyrimidine radical; treatment of viral infections
US5466806A (en) * 1989-02-08 1995-11-14 Biochem Pharma Inc. Processes for preparing substituted 1,3-oxathiolanes with antiviral properties
US6175008B1 (en) * 1988-04-11 2001-01-16 Biochem Pharma Inc. Processes for preparing substituted 1,3-oxathiolanes with antiviral properties
US5270315A (en) * 1988-04-11 1993-12-14 Biochem Pharma Inc. 4-(purinyl bases)-substituted-1,3-dioxlanes
US5041449A (en) * 1988-04-11 1991-08-20 Iaf Biochem International, Inc. 4-(nucleoside base)-substituted-1,3-dioxolanes useful for treatment of retroviral infections
US4900828A (en) * 1988-05-12 1990-02-13 Hoffmann-Laroche Inc. Intermediate compounds and an improved procedure for the synthesis of 2',3'-dideoxycytidine
CA1318627C (en) * 1988-07-14 1993-06-01 Jeffrey M. Howell Enzymatic resolution process
US5106750A (en) * 1988-08-30 1992-04-21 G. D. Searle & Co. Enantio- and regioselective synthesis of organic compounds using enol esters as irreversible transacylation reagents
JPH0269476A (en) * 1988-09-06 1990-03-08 Kohjin Co Ltd Production of pyrimidine derivative
JPH0269469A (en) * 1988-09-06 1990-03-08 Kohjin Co Ltd Dihydrofuran derivative and production thereof
GB8822546D0 (en) * 1988-09-26 1988-11-02 Wellcome Found Antiviral combinations
JP2788084B2 (en) * 1988-12-19 1998-08-20 ザ ウエルカム フアウンデーシヨン リミテツド Antiviral compounds
ES2196004T3 (en) * 1989-02-08 2003-12-16 Iaf Biochem Int PROCEDURE TO PREPARE 1,3-OXATIOLANS SUBSTITUTED WITH ANTIVIRAL PROPERTIES.
NZ233197A (en) * 1989-04-13 1991-11-26 Richard Thomas Walker Aromatically substituted nucleotide derivatives, intermediates therefor and pharmaceutical compositions
US5059690A (en) * 1990-03-01 1991-10-22 E. R. Squibb & Sons, Inc. Purinyl tetrahydrofurans
CA2023856A1 (en) * 1989-09-26 1991-03-27 Jeffrey M. Howell Enzymatic resolution process
US5071983A (en) * 1989-10-06 1991-12-10 Burroughs Wellcome Co. Therapeutic nucleosides
IE904378A1 (en) * 1989-12-20 1991-07-03 Abbott Lab Analogs of oxetanyl purines and pyrimidines
US5914331A (en) * 1990-02-01 1999-06-22 Emory University Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane
US5700937A (en) * 1990-02-01 1997-12-23 Emory University Method for the synthesis, compositions and use of 2'-deoxy-5-fluoro-3'-thiacytidine and related compounds
US5204466A (en) * 1990-02-01 1993-04-20 Emory University Method and compositions for the synthesis of bch-189 and related compounds
US6703396B1 (en) * 1990-02-01 2004-03-09 Emory University Method of resolution and antiviral activity of 1,3-oxathiolane nuclesoside enantiomers
US6069252A (en) * 1990-02-01 2000-05-30 Emory University Method of resolution and antiviral activity of 1,3-oxathiolane nucleoside enantiomers
US5276151A (en) * 1990-02-01 1994-01-04 Emory University Method of synthesis of 1,3-dioxolane nucleosides
GB9009861D0 (en) * 1990-05-02 1990-06-27 Glaxo Group Ltd Chemical compounds
US5587480A (en) * 1990-11-13 1996-12-24 Biochem Pharma, Inc. Substituted 1,3-oxathiolanes and substituted 1,3-dithiolanes with antiviral properties
IT1246983B (en) * 1990-11-13 1994-12-12 Consiglio Nazionale Ricerche L-2'-DESOXYURIDINE AND PHARMACEUTICAL COMPOSITIONS THAT CONTAIN IT.
US5248776A (en) * 1990-12-05 1993-09-28 University Of Georgia Research Foundation, Inc. Process for enantiomerically pure β-L-1,3-oxathiolane nucleosides
US5179104A (en) * 1990-12-05 1993-01-12 University Of Georgia Research Foundation, Inc. Process for the preparation of enantiomerically pure β-D-(-)-dioxolane-nucleosides
US5444063A (en) * 1990-12-05 1995-08-22 Emory University Enantiomerically pure β-D-dioxolane nucleosides with selective anti-Hepatitis B virus activity
US5925643A (en) * 1990-12-05 1999-07-20 Emory University Enantiomerically pure β-D-dioxolane-nucleosides
WO1992010496A1 (en) * 1990-12-05 1992-06-25 University Of Georgia Research Foundation, Inc. ENANTIOMERICALLY PURE β-L-(-)-1,3-OXATHIOLANE NUCLEOSIDES
IL100502A (en) * 1991-01-03 1995-12-08 Iaf Biochem Int Pharmaceutical compositions containing cis-4-amino-1(hydroxymethyl-1,3-oxathiolan-5-yl)-1H-pyrimid-2-one nucleoside or its derivatives
IL100965A (en) * 1991-02-22 1999-12-31 Univ Emory 2-Hydroxymethyl-5-(5-fluorocytosin-l-yl)-1,3-oxathiolane its resolution and pharmaceutical compositions containing it
CA2105486C (en) * 1991-03-06 2003-10-28 George Robert Painter Iii Therapeutic nucleosides
GB9104740D0 (en) * 1991-03-06 1991-04-17 Wellcome Found Antiviral nucleoside combination
WO1992018517A1 (en) * 1991-04-17 1992-10-29 Yale University Method of treating or preventing hepatitis b virus
GB9110874D0 (en) * 1991-05-20 1991-07-10 Iaf Biochem Int Medicaments
ZA923640B (en) * 1991-05-21 1993-02-24 Iaf Biochem Int Processes for the diastereoselective synthesis of nucleosides
GB9111902D0 (en) * 1991-06-03 1991-07-24 Glaxo Group Ltd Chemical compounds
GB9116601D0 (en) * 1991-08-01 1991-09-18 Iaf Biochem Int 1,3-oxathiolane nucleoside analogues
GB9307013D0 (en) * 1993-04-02 1993-05-26 Wellcome Found Therapeutic combinations
SE510803C2 (en) * 1994-12-13 1999-06-28 Volvo Ab Pressure-operated actuator
US5639787A (en) * 1995-02-28 1997-06-17 The Center For The Improvement Of Human Functioning Int'l, Inc. Therapeutic method for the treatment of cancer

Also Published As

Publication number Publication date
MC2233A1 (en) 1993-02-23
NO2008011I1 (en) 2008-07-28
EP0513200A1 (en) 1992-11-19
NL300148I1 (en) 2004-07-01
CA2481078A1 (en) 1991-08-08
HU211300A9 (en) 1995-11-28
ES2279559T3 (en) 2007-08-16
FI121069B (en) 2010-06-30
JPH05505794A (en) 1993-08-26
ATE170750T1 (en) 1998-09-15
US5204466A (en) 1993-04-20
JP2006141408A (en) 2006-06-08
AU2006207874A1 (en) 2006-09-28
NL300148I2 (en) 2004-11-01
DE69133556T2 (en) 2007-08-16
AU2010201878A1 (en) 2010-05-27
NO2008011I2 (en) 2010-10-18
HK1014664A1 (en) 1999-09-30
AU7300491A (en) 1991-08-21
CA2075189A1 (en) 1991-08-02
NO326249B1 (en) 2008-10-27
JP4496377B2 (en) 2010-07-07
EP0872237A1 (en) 1998-10-21
HUT62566A (en) 1993-05-28
US5539116A (en) 1996-07-23
ES2076130T5 (en) 2004-12-16
NO923014L (en) 1992-07-30
EP1772151A2 (en) 2007-04-11
AU2002300661B2 (en) 2006-06-08
JP3530150B2 (en) 2004-05-24
JP2001019690A (en) 2001-01-23
DK0513200T3 (en) 1999-05-25
GR950300024T1 (en) 1995-06-30
CA2075189C (en) 2004-11-30
AU698859C (en) 2003-01-30
CA2678778A1 (en) 1991-08-08
FI20060622A (en) 2006-06-27
WO1991011186A1 (en) 1991-08-08
NO20083728L (en) 1992-07-30
JP2002012591A (en) 2002-01-15
JP2005053893A (en) 2005-03-03
ES2076130T3 (en) 1999-03-01
US6153751A (en) 2000-11-28
EP1772151A3 (en) 2007-06-13
BG62236B1 (en) 1999-06-30
RO108564B1 (en) 1994-06-30
DE513200T1 (en) 1995-07-13
LU91073I2 (en) 2004-04-23
DK0513200T4 (en) 2004-07-05
HU9202496D0 (en) 1992-12-28
FI20050672A (en) 2005-06-22
ES2076130T1 (en) 1995-11-01
CA2481078C (en) 2009-12-15
AU2006207874B2 (en) 2010-02-11
EP0872237B1 (en) 2007-01-17
DE69130166T2 (en) 1999-04-08
US5814639A (en) 1998-09-29
NO970385D0 (en) 1997-01-29
FI116222B (en) 2005-10-14
EP0513200B1 (en) 1998-09-09
AU658136B2 (en) 1995-04-06
FI923446A (en) 1992-07-30
DE69130166D1 (en) 1998-10-15
DE69130166T3 (en) 2005-04-14
AU658136C (en) 2003-06-12
DK0872237T3 (en) 2007-04-23
NO313048B1 (en) 2002-08-05
US5210085A (en) 1993-05-11
NO923014D0 (en) 1992-07-30
AU698859B2 (en) 1998-11-12
FI114471B (en) 2004-10-29
DE122004000015I2 (en) 2004-11-18
US5914400A (en) 1999-06-22
NO20065640L (en) 1992-07-30
AU4474599A (en) 1999-11-11
NO970386L (en) 1992-07-30
JP3844978B2 (en) 2006-11-15
RU2125558C1 (en) 1999-01-27
EP0513200A4 (en) 1993-04-07
JPH07618B2 (en) 1995-01-11
NO324979B1 (en) 2008-01-14
KR100188357B1 (en) 1999-06-01
US20050004148A1 (en) 2005-01-06
US6114343A (en) 2000-09-05
EP0513200B2 (en) 2004-04-28
KR920703582A (en) 1992-12-18
NO970385L (en) 1992-07-30
JP2001352997A (en) 2001-12-25
DE122004000015I1 (en) 2004-08-12
DE69133556D1 (en) 2007-03-08
NO970386D0 (en) 1997-01-29
AU4031995A (en) 1996-04-26
KR100381705B1 (en) 2003-04-26
FI20030933A (en) 2003-06-24
HU227485B1 (en) 2011-07-28
JP4108645B2 (en) 2008-06-25

Similar Documents

Publication Publication Date Title
FI923446A (en) FOERFARANDE OCH KOMPOSITIONER FOER SYNTES AV BCH-189 OCH LIKNANDE FOERENINGAR.
ATE214707T1 (en) 5-HALO-5-DEOXY-SORBOPYRANOSE COMPOUNDS

Legal Events

Date Code Title Description
FG Patent granted

Ref document number: 114471

Country of ref document: FI